Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Experimental and Therapeutic Medicine
Join Editorial Board Propose a Special Issue
Print ISSN: 1792-0981 Online ISSN: 1792-1015
Journal Cover
November-2017 Volume 14 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2017 Volume 14 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro

  • Authors:
    • Jianqing Lin
    • Zhiyao Chen
    • Zhijun Huang
    • Feng Chen
    • Zeyi Ye
    • Shaoze Lin
    • Weidong Wang
  • View Affiliations / Copyright

    Affiliations: Department of Surgical Oncology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou, Fujian 362000, P.R. China
    Copyright: © Lin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 4194-4200
    |
    Published online on: September 1, 2017
       https://doi.org/10.3892/etm.2017.5090
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

As a unique member of the cadherin superfamily, T‑cadherin (T‑cad) has been demonstrated to be associated with gastric cancer (GC) prognosis. To elucidate the function of T‑cad in GC in vitro, the present study firstly examined T‑cad protein expression in normal and gastric cancer tissues and cell lines, and it was demonstrated to be significantly downregulated in gastric cancer samples compared with normal samples. Control and T‑cad expression vectors were then transfected into the MGC8‑03 and AGS GC cell lines. Utilizing MTT, clonogenic, flow cytometry, wound healing and Transwell invasion assays in addition to Western blotting, the present study demonstrated that the overexpression of T‑cad suppressed GC cell growth and colony formation via cell cycle arrest at the G0/G1 phase via downregulating the expression of cyclin dependent kinase 4 and Cyclin D1. In addition, overexpression of T‑cad significantly inhibited GC cell migration and invasion by increasing E‑cadherin and decreasing Vimentin expression. These findings suggest T‑cad may be important in GC cell proliferation and metastasis and serve as a promising target for the treatment of GC in the future.

Introduction

Gastric cancer (GC), as a common gastrointestinal tumor, is one of the leading causes of cancer related mortality worldwide, particularly in East Asian countries, including China and Japan (1–3). Although surgical resection combined with adjuvant therapy has achieved advances, the 5-year survival rate remains less than 30%, causing unsatisfactory clinical outcome of GC patients (4,5). The main reason is that most patients are diagnosed as unresectable advanced or metastatic stage (6), which make it difficult to improve the early diagnosis and effective treatment for GC. Currently, studies have shown that the initiation and development of GC is closely associated with a sequential accumulation of various molecular and genetic alterations (7,8). Therefore, it is urgently needed to investigate the underlying molecular mechanisms of initiation and metastasis to develop appropriate approaches for improving its diagnosis and treatment.

Cadherins are members of a large family of transmemrane glycoproteins that play an important role in the maintenance of normal tissue architecture by mediating specific cell-cell adhesion, cell recognition and signaling (9,10). Accumulating evidences have shown that perturbations in cadherins are implicated in tumor development, especially in invasion and metastasis (11) as putative products of tumor suppressor genes (12–15). For T-cadherin (T-cad, also known as CDH13 or H-cadherin) is a unique atypical glycosylphosphatidylinositol (GPI)-anchored member of classical cadherin superfamily, which lacks the highly conserved transmembrane and cytoplasmic domains (16–18). Recently, interest in the role of T-cad in human malignancies is increasing. T-cad has been found to be downregulated in lung cancer, ovarian cancer, bladder cancer, cervical and prostate cancer, but abundantly expressed in hepatocellular carcinoma and osteosarcoma (19). Moreover, T-cad could regulate progression of tumor types including breast, hepatic and skin carcinomas by modulating tumor cell proliferation and migration (18). In breast cancer, overexpression of T-cad markedly reduced cell invasive potential and growth rate (20). Wang et al demonstrated reduction of T-cad facilitated tumorigenicity in prostate cancer (21). Notably, T-cad could exert pleiotropic effects to promote tumor growth through different mechanisms on cancer cells in vitro and vivo (22). Although previous studies indicated T-cad is frequently deleted in human GC and decreased T-cad is associated with GC poor prognosis (23,24), little is known about the biological effects of T-cad in GC.

In this study, we showed that T-cad was downregulated in GC tissues and cell lines. Then the effects of T-cad overexpression on the cell proliferation, cell cycle, migration and invasion were further evaluated in GC cells in vitro. Our data indicate that T-cad is involved in uncontrolled cell proliferation and invasion of GC cells by, at least in part, influencing cell growth and motility.

Materials and methods

GC tissue specimens and cell lines

The GC tissue and adjacent noncancerous tissue were collected from patients who underwent surgical resection in our hospital. The fresh tissue samples were immediately snapped-frozen in liquid nitrogen and stored at −80°C for further analysis.

Human GC cell lines, MGC80-3, SGC-7901, AGS, HGC27 and normal human immortalized normal gastric epithelial cell line GES-1 were obtained from the Cancer Research Institution of China Medical University. All of these cell lines were cultured in RPMI-1640 medium (Hyclone, Logan, UT, USA) containing 10% fetal bovine serum (FBS; HyClone), 10 units/ml penicillin and 10 mg/ml streptomycin, and incubated in a 5% CO2 incubator at 37°C.

T-cad overexpressing in GC cell lines

The plasmids for pcDNA3.1 and pcDNA-T-cadherin (pcDNA-Tcad; Invitrogen Life Technologies, Carlsbad, CA, USA) were purchased and respectively transfected into GC cell lines, MGC80-3 and AGS using Lipofectamine® 2000 (Invitrogen Life Technologies) according to manufacturer's instructions. Then stably transfected cells were obtained and cultured for 48 h before confirming the expression of T-cad by qRT-PCR and western blotting.

RNA isolation and qRT-PCR

Total RNA was isolated from tissues or cells using the RNeasy Mini kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The gene-specific primers were as follows: T-cad, forward: 5′-TTCAGCAGAAAGTGTTCCATAT-3′, reverse: 5′-GTGCATGGACGAACAGAGT-3′; GAPDH, forward: 5′-GACCCCTTCATTGACCTCAACTAC-3′, reverse: 5′-TGGTGGTGCAGGATGCATTGCTGA-3′. The qRT-PCR was performed on a Fast Real-time PCR 7500 System (Applied Biosystems Life Technologies, Foster City, CA, USA) by using SYBR-Green PCR Master Mix following the reaction procedure: 1 min at 95°C, 40 cycles of 95°C for 5 sec, and 60°C for 20 sec. Gene expression was normalized to the expression of GAPDH by the 2−ΔΔCq method (25). Each experiment was performed in triplicate and repeated three times.

Protein extraction and western blot

Total proteins were extracted from tissues or cells using RIPA lysis buffer (Beyotime Institute of Biotechnology, Shanghai, China). Enhanced BCA Protein Assay Kit (Beyotime Institute of Biotechnology) was used to quantify the protein concentration. Then equivalent proteins of each sample were separated by SDS-PAGE on 10% polyacrylamide gels and transfered to polyvinylidene fluoride membranes (Millipore Corp., Billerica, MA, USA). The membranes were blocked in PBS containing 5% non-fat milk for 2 h at room temperature, and then incubated with primary antibodies, including anti-T-cad (1:1,000; Abcam, Cambridge, MA, USA), anti-CDK4, anti-Cyclin D1, anti-E-cadherin, anti-Vimentin and anti-GAPDH overnight at 4°C. After washing three times with PBS for 5 min, membranes were incubated with the corresponding horseradish peroxidase-conjugated secondary antibodies for 1 h at room temperature. After washing, the target proteins were visualized by an enhanced chemiluminescence detection system. GAPDH was used as an internal control.

Cell viability and colony formation assays

MTT assays were performed every day to determine cell viability in GC cells over the following 5 days. Briefly, cells were seeded in 96-well plates at a density of 2×103 cells per well and incubated with 20 µl MTT (0.5 mg/ml, Sigma, USA) for 4 h at 37°C. Then, 150 µl dimethylsulfoxide (DMSO; Sigma, St. Louis, MO, USA) was added to dissolve the purple formazan crystals for 1 h. Finally, the absorbance of each well was read on an ELISA reader (Bio-Rad, Berkeley, CA, USA) at a wavelength of 595 nm.

For the colony formation assay, cells (500 cells per well) were cultured in 6-well plates after 48 h transfection. After 7 day culture, the cells were fixed in 4% paraformaldehyde and then stained with crystals purple (Sigma). Surviving colonies (>50 cells per colony) were then observed and manually counted through a light microscope. Each experiment was performed in triplicate and repeated three times.

Cell cycle assay

The cell cycle distribution was analyzed by flow cytometry using PI staining. Briefly, cells were seeded in 6-cm dishes after 48 h transfection at a density of 2×105 cells per dish. Then cells were washed with cold PBS for three times and fixed in 70% ethanol at 4°C for 24 h. After washed with PBS again, cells were then stained with PBS containing 0.05 mg/ml of PI and RNase A (Beyotime Institute of Biotechnology) for 30 min in the dark. Then cells were determined for DNA content using a FACSCalibur (BD Biosciences, San Diego, CA, USA) and data were analyzed with the ModFit DNA software. Each experiment was performed in triplicate and repeated three times.

Wound healing assay

For wound-healing-assay, cells were seeded into 6-well plates and culture overnight until grown to approximately 90% confluence. Then cells were scratched by a 10-µl sterile plastic tip in a definite array. After washing the well with PBS, the cells migrating into the wounded areas were observed and photographed under a fluorescence microscope at 0 and 48 h time points. The cell wound healing rate was evaluated by calculating the percentage of the wound area compared with the area of total cells. Each experiment was performed in triplicate and repeated three times.

Transwell migration and invasion assays

The cell migration assay was performed using a Transwell chambers (8-µm pore size; Corning Inc., Acton, MA, USA). At 48 h after transfection, a total of 1×105 cells were trypsinized and added to the upper chamber in serum-free medium, and culture medium containing 10% FBS was added into the lower chamber. After incubating for 24 h, the cells that migrated into the lower chamber were fixed with 4% paraformaldehyde and stained with crystal violet. Finally, cells were photographed and counted under a microscope. For the cell invasion assay, the procedure was similar to the cell migration assay, except the Transwell chambers were coated with 200 µl of Matrigel. Each experiment was performed in triplicate and repeated three times.

Statistical analysis

All quantitative data were expressed as mean ± standard deviation (SD) of three independent experiments. Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software, Inc., La Jolla, CA, USA). The differences between two groups were evaluated using the Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Relative low levels of T-cad expression in GC tissues and cell lines

To investigate T-cad expression in GC, 8 pairs of GC and corresponding adjacent noncancerous tissues were collected and the basic clinicopathologic features of patients were summarized in Table I. Then these tissues were subjected to qRT-PCR and western blotting analyses. As shown in Fig. 1A, the mRNA levels of T-cad were significantly downregulated in GC tissues compared with adjacent noncancerous tissues (P=0.0041). In line with this result, clearly decreased levels of T-cad protein were detected in all the tumors tissues in comparison to the paired noncancerous tissues (Fig. 1B). In addition, we examined the expression of T-cad in several GC cell lines. As presented in Fig. 1C and D, the levels of T-cad mRNA and protein in GC cell lines was much lower than that in normal GES-1 cells, of which MGC80-3 and AGS exhibited the lowest signals of T-cad than the other GC cell lines. These data suggested that T-cad might serve as a tumor suppressor in GC.

Figure 1.

T-cadherin is downregulated in GC tissues and cell lines. The mRNA and protein levels of T-cadherin in GC tissues and adjacent noncancerous tissues were determined using (A) qRT-PCR and (B) western blotting analyses, respectively. The (C) qRT-PCR and (D) western blotting were used to measure the mRNA and protein levels of T-cadherin in GC cell lines (MGC80-3, SGC-7901, HGC27 and AGS) and normal GES-1 cell line, respectively. Quantitative data were expressed as mean ± standard deviation of three independent experiments. GC, gastric cancer; N, adjacent noncancerous tissues; T, GC tissues; GAPDH serves as an internal control.

Table I.

The clinicopathologic factors of gastric cancer (n=8).

Table I.

The clinicopathologic factors of gastric cancer (n=8).

CharacteristicsCases
Age (years)
  <505
  ≥503
Gender
  Male2
  Female6
TNM stage
  I, II5
  III, IV3
Tumor site
  Upper2
  Middle3
  Low3
Overexpression of T-cad suppressed cellular proliferation ability in GC cells

We successfully constructed stable clones overexpressing T-cad from MGC80-3 and AGS with lower signals of T-cad. As shown in Fig. 2A and B, overexpression of T-cad in the two GC cell lines were confirmed by western blotting after transfection for 48 h. Then MTT and colony formation assays were performed to determine cell proliferation ability. The results showed that GC cell viability was dramatically decreased in T-cad overexpression group compared with the empty vector group in MGC80-3 (Fig. 2C) and AGS (Fig. 2D) cells after transfection for 4 and 5 days (P<0.001). Consistent with the MTT assay, colony formation assay also indicated that T-cad overexpression led to an obvious reduction of colony number in MGC80-3 (Fig. 2E) and AGS (Fig. 2F) cells. Collectively, these findings supports that T-cad could inhibit cell proliferation in GC.

Figure 2.

T-cadherin inhibits GC cell proliferation. Overexpression of T-cadherin protein in transfected cell lines, (A) MGC80-3 and (B) AGS was confirmed by western blotting. MTT assay was used to measure cell viability in (C) MGC80-3 and (D) AGS after transfection with empty vector pcDNA or pcDNA-T-cadherin (pcDNA-Tcad). These data are shown as the mean ± standard deviation of three independent experiments. The size and number of colonies formed in (E) MGC80-3 and (F) AGS cells recorded under a light microscope. The representative pictures shown are from one of three independent experiments. ***P<0.001 vs. control or empty vector pcDNA.

Overexpression of T-cad induced cell cycle G0/G1 arrest in GC

Next, we investigated the mechanisms underlying the growth suppression effects of T-cad overexpression by analyzing cell cycle distribution of GC cells via a flow cytometer. As shown in Fig. 3A, the percentage of cells in G0/G1 phase was significantly increased, but in S phase was remarkably decreased in T-cad overexpression group, compared with control and empty vector groups in MGC80-3 cells (P<0001). Similar results were also found in AGS cells (Fig. 3B, P<0.001, P<0.01). The data revealed that T-cad overexpression could arrest cell cycle at G0/G1 phase, which might be closely associated with growth suppression effects.

Figure 3.

T-cadherin arrested cell cycle at G0/G1 phase in GC cells. Flow cytometry was used to analyze cell cycle distribution in empty vector pcDNA or pcDNA-T-cadherin (pcDNA-Tcad)-transfected (A) MGC80-3 and (B) AGS cells. Left panel shows representative dot plots and right panels show the quantitative analysis. These data are shown as the mean ± standard deviation of three independent experiments. **P<0.01, ***P<0.001 vs. control or empty vector pcDNA.

Overexpression of T-cad reduced cellular motility, migration and invasion in GC

In addition to cell proliferation, we also performed wound-healing and transwell assays to determine the effects of T-cad on GC cell metastatic ability. As shown in Fig. 4A, an evident acceleration in the wound closure rate was observed in control group or empty vector groups compared with cells following pcDNA-Tcad transfection. Quantitative analysis further demonstrated that the wound areas was significantly larger in T-cad overexpression group compared with control group or empty vector group in MGC80-3 cells after incubation for 48 h (P<0001). In transwell assay, the number of migrated cells in pcDNA-Tcad group was significantly reduced compared with the control group or empty vector group MGC80-3 cells (Fig. 4B, P<0.05). Subsequently, cell invasion was determined and the results indicated that the invasive ability of MGC80-3 cells was remarkably suppressed by T-cad overerxpression (Fig. 4C, P<0.01). These consistent results suggested that T-cad could inhibit tumor cell migration and invasion in GC.

Figure 4.

T-cadherin suppressed GC cell motility, migration and invasion. (A) Wound-healing assay was used to evaluate motility of cells transfected with control, empty vector pcDNA, pcDNA-Tcad. The wound area was visualized and calculated at 1 and 48 h. (B) Cell migration transfected with control, empty vector pcDNA, pcDNA-Tcad was examined by transwell assay. (C) The cell invasive ability transected with control, empty vector pcDNA, pcDNA-Tcad was determined by Matrigel cell culture chambers. These data are shown as the mean ± standard deviation of three independent experiments. *P<0.05, **P<0.01, ***P<0.001 vs. control or empty vector pcDNA.

Overexpression of T-cad regulated cell cycle and metastatic markers

To gain insights into the molecular mechanism of the tumor-suppressive effect of T-cad, we detected the expression alterations of some cell cycle regulators and motility markers using Western blotting. As shown in Fig. 5, the expression levels of CDK4 and Cyclin D1, associated with G1-S transition, were obviously downregulated in pcDNA-Tcad group. Furthermore, inhibition of metastasis by T-cad overexpression resulted from downregulation of Vimentin and upregulation of E-cadherin. These results suggest that T-cad inhibits cell proliferation, migration and invasion might by regulating the expression of important markers involved in cell cycle, migration and invasion.

Figure 5.

Effect of T-cadherin on markers associated with cell cycle progression and metastatic potential in GC. Western blotting was used to analyze the expression of CDK4, Cyclin D1, E-cadherin, Vimentin and MMP2 in MGC80-3 cells following control, empty vector pcDNA, pcDNA-Tcad transfection, respectively. GAPDH serves as an internal control.

Discussion

T-cad gene is a novel adhesion molecule found to map to chromosome 16q24, a region often exhibiting loss of heterozygosity in cancer including breast, prostate cancer and others (26–28). Recently, it has been reported to be an important independent prognostic predictor in GC. However, its potential biological role in GC remains not fully understood. In this study, we showed that the mRNA and protein expression levels of T-cad were significantly lower in the GC tissues and cell lines compared with controls, which is agreement with the previous reports about decreased T-cad in GC (23,29). Furthermore, we performed gain-of-function assay on GC cells to investigate the biological effects of T-cad on cell proliferation, migration and invasion in vitro. It was found that the proliferative and motility activity of GC cells decreased by T-cad overexpression. Consistent with our data, most studies have shown that enhanced T-cad cDNA expression inhibited tumor cell growth, whereas T-cad silencing stimulated proliferation, invasion and metastasis in several in vitro and in vivo models (22,30–32).

It has been suggested that T-cad may affect cell proliferation through regulating cell cycle progression, as demonstrated by Ivanov et al (33) and Zhong et al (34). To further investigate the underlying mechanism of the growth inhibition effect of T-cad, we determined whether T-cad overexpression had an impact on cell cycle distribution. As expect, T-cad overexpression induced cell cycle arrest at G0/G1 phase through downregulation of CDK4 and Cyclin D1 expression in GC cells. Interestingly, T-cad could negatively regulates the cell proliferation by inducing a delay in the G2/M phase in squamous carcinoma (35) and astrocytomas (36). The different cell cycle arrest mechanisms might be ascribed to different tumor types.

In addition, T-cad encodes a cell surface glycoprotein belonging to the cadherin family responsible for selective cell recognition and adhesion. In human tumors, cell-cell association is often disorganized and thought to be a cause of the unregulated invasion and metastasis behavior of tumor cells (37,38). Therefore, we speculate T-cad might be associated with GC cell migration and invasion. As speculated, our results showed that T-cad overexpression suppressed GC cell migration and invasion by upregulating E-cadherin expression and downregulation the expression of Vimentin and MMP-2. E-cadherin, another of the cadherin family, is an essential adhesive tumor suppressor as the hallmark of epithelial-mesenchymal transition (EMT) (39). Recently, it was reported that loss of E-cadherin promotes tumor metastatic and DNA methylation-induced silencing is significantly correlated with increased invasive potential of melanoma cells (40). Moreover, a significant correlation was found between reduced levels of E-cadherin via promoter aberrant methylation and several poor prognostic factors, namely ulceration, head/neck localization, mitotic count, metastasis and reduced overall/disease-free survival in cutaneous melanoma. Likewise, these above poor prognostic factors are frequently associated with epigenetic downregulation of E-cadherin in mucosal or uveal melanoma (40). These evidences further demonstrated E-cadherin plays a crucial role in the events affeting melanoma progression and might be considered as a prognostic factor for melanoma. In addition, the promoter of E-cadherin frequently underwent hypermethylation in human GC accompanied by inactivation of T-cad, suggesting their positive correlation in GC (41,42). Vimentin, as an intermediate filament during EMT, is required for facilitating mesenchymal cell migration (43). Given the evidence discussed, our findings of their correlation suggest that T-cad might play an important role in GC metastasis by positively regulating E-cadherin expression and negatively regulating Vimentin expression.

Collectively, our study revealed the preliminary biological function of T-cad in GC cells and found restoration of T-cad obviously suppressed GC cell biological behaviors by inhibiting cell proliferation and motility. Our studies suggest that T-cad might represent an important target for GC treatment. In addition, some additional limitations are presented in this study. Firstly, the mRNA determination of CDK4, Cyclin D1, Vimentin and E-cadherin levels following ectopic expression of T-cad was nor performed. Secondly, the luciferase assay was absent not to demonstrate whether T-cadherin directly or indirectly regulated these downstream molecules. Therefore, still further analysis of T-cad regulation in GC will be the aim of or future work.

Acknowledgements

The present study was supported by funding from the Medical Foundation of Fujian (no. 2015J01439).

References

1 

Piazuelo MB and Correa P: Gastric cáncer: Overview. Colomb Med (Cali). 44:192–201. 2013.PubMed/NCBI

2 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

3 

Sugano K: Screening of gastric cancer in Asia. Best Pract Res Clin Gastroenterol. 29:895–905. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Xia P, Song CL, Liu JF, Wang D and Xu XY: Prognostic value of circulating CD133(+) cells in patients with gastric cancer. Cell Prolif. 48:311–317. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Gigek CO, Chen ES, Calcagno DQ, Wisnieski F, Burbano RR and Smith MA: Epigenetic mechanisms in gastric cancer. Epigenomics. 4:279–294. 2012. View Article : Google Scholar : PubMed/NCBI

6 

Zhu W, Ye L, Zhang J, Yu P, Wang H, Ye Z and Tian J: PFK15, a small molecule inhibitor of PFKFB3, induces cell cycle arrest, apoptosis and inhibits invasion in gastric cancer. PLoS One. 11:e01637682016. View Article : Google Scholar : PubMed/NCBI

7 

Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y and Oue N: Molecular pathology of gastric cancer: Research and practice. Pathol Res Pract. 207:608–612. 2011. View Article : Google Scholar : PubMed/NCBI

8 

Baniak N, Senger JL, Ahmed S, Kanthan SC and Kanthan R: Gastric biomarkers: A global review. World J Surg Oncol. 14:2122016. View Article : Google Scholar : PubMed/NCBI

9 

Nagafuchi A, Tsukita S and Takeichi M: Transmembrane control of cadherin-mediated cell-cell adhesion. Semin Cell Biol. 4:175–181. 1993. View Article : Google Scholar : PubMed/NCBI

10 

Takeichi M: Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 251:1451–1455. 1991. View Article : Google Scholar : PubMed/NCBI

11 

Wheelock MJ and Johnson KR: Cadherins as modulators of cellular phenotype. Annu Rev Cell Dev Biol. 19:207–235. 2003. View Article : Google Scholar : PubMed/NCBI

12 

Takeichi M: Cadherins in cancer: Implications for invasion and metastasis. Curr Opin Cell Biol. 5:806–811. 1993. View Article : Google Scholar : PubMed/NCBI

13 

Mayer B, Johnson JP, Leitl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W and Funke I: E-cadherin expression in primary and metastatic gastric cancer: Down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 53:1690–1695. 1993.PubMed/NCBI

14 

Bringuier PP, Umbas R, Schaafsma HE, Karthaus HF, Debruyne FM and Schalken JA: Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors. Cancer Res. 53:3241–3245. 1993.PubMed/NCBI

15 

Oka H, Shiozaki H, Kobayashi K, Inoue M, Tahara H, Kobayashi T, Takatsuka Y, Matsuyoshi N, Hirano S, Takeichi M, et al: Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 53:1696–1701. 1993.PubMed/NCBI

16 

Angst BD, Marcozzi C and Magee AI: The cadherin superfamily: Diversity in form and function. J Cell Sci. 114:629–641. 2001.PubMed/NCBI

17 

Takeuchi T and Ohtsuki Y: Recent progress in T-cadherin (CDH13, H-cadherin) research. Histol Histopathol. 16:1287–1293. 2001.PubMed/NCBI

18 

Philippova M, Joshi MB, Kyriakakis E, Pfaff D, Erne P and Resink TJ: A guide and guard: The many faces of T-cadherin. Cell Signal. 21:1035–1044. 2009. View Article : Google Scholar : PubMed/NCBI

19 

Andreeva AV and Kutuzov MA: Cadherin 13 in cancer. Genes Chromosomes Cancer. 49:775–790. 2010.PubMed/NCBI

20 

Lee SW: H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. Nat Med. 2:776–782. 1996. View Article : Google Scholar : PubMed/NCBI

21 

Wang XD, Wang BE, Soriano R, Zha J, Zhang Z, Modrusan Z, Cunha GR and Gao WQ: Expression profiling of the mouse prostate after castration and hormone replacement: Implication of H-cadherin in prostate tumorigenesis. Differentiation. 75:219–234. 2007. View Article : Google Scholar : PubMed/NCBI

22 

Pfaff D, Philippova M, Kyriakakis E, Maslova K, Rupp K, Buechner SA, Iezzi G, Spagnoli GC, Erne P and Resink TJ: Paradoxical effects of T-cadherin on squamous cell carcinoma: Up- and down-regulation increase xenograft growth by distinct mechanisms. J Pathol. 225:512–524. 2011. View Article : Google Scholar : PubMed/NCBI

23 

Tang Y, Dai Y and Huo J: Decreased expression of T-cadherin is associated with gastric cancer prognosis. Hepatogastroenterology. 59:1294–1298. 2012.PubMed/NCBI

24 

Mori Y, Matsunaga M, Abe T, Fukushige S, Miura K, Sunamura M, Shiiba K, Sato M, Nukiwa T and Horii A: Chromosome band 16q24 is frequently deleted in human gastric cancer. Br J Cancer. 80:556–562. 1999. View Article : Google Scholar : PubMed/NCBI

25 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

26 

Lindblom A, Rotstein S, Skoog L, Nordenskjöld M and Larsson C: Deletions on chromosome 16 in primary familial breast carcinomas are associated with development of distant metastases. Cancer Res. 53:3707–3711. 1993.PubMed/NCBI

27 

Carter BS, Ewing CM, Ward WS, Treiger BF, Aalders TW, Schalken JA, Epstein JI and Isaacs WB: Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc Natl Acad Sci USA. 87:8751–8755. 1990. View Article : Google Scholar : PubMed/NCBI

28 

Chen T, Sahin A and Aldaz CM: Deletion map of chromosome 16q in ductal carcinoma in situ of the breast: Refining a putative tumor suppressor gene region. Cancer Res. 56:5605–5609. 1996.PubMed/NCBI

29 

Wei B, Shi H, Lu X, Shi A, Cheng Y and Dong L: Association between the expression of T-cadherin and vascular endothelial growth factor and the prognosis of patients with gastric cancer. Mol Med Rep. 12:2075–2081. 2015. View Article : Google Scholar : PubMed/NCBI

30 

Pfaff D, Philippova M, Buechner SA, Maslova K, Mathys T, Erne P and Resink TJ: T-cadherin loss induces an invasive phenotype in human keratinocytes and squamous cell carcinoma (SCC) cells in vitro and is associated with malignant transformation of cutaneous SCC in vivo. Br J Dermatol. 163:353–363. 2010. View Article : Google Scholar : PubMed/NCBI

31 

Bosserhoff AK, Ellmann L, Quast AS, Eberle J, Boyle GM and Kuphal S: Loss of T-cadherin (CDH-13) regulates AKT signaling and desensitizes cells to apoptosis in melanoma. Mol Carcinog. 53:635–647. 2014.PubMed/NCBI

32 

Philippova M, Pfaff D, Kyriakakis E, Buechner SA, Iezzi G, Spagnoli GC, Schoenenberger AW, Erne P and Resink TJ: T-cadherin loss promotes experimental metastasis of squamous cell carcinoma. Eur J Cancer. 49:2048–2058. 2013. View Article : Google Scholar : PubMed/NCBI

33 

Ivanov D, Philippova M, Allenspach R, Erne P and Resink T: T-cadherin upregulation correlates with cell-cycle progression and promotes proliferation of vascular cells. Cardiovasc Res. 64:132–143. 2004. View Article : Google Scholar : PubMed/NCBI

34 

Zhong Y, Lopez-Barcons L, Haigentz M Jr, Ling YH and Perez-Soler R: Exogenous expression of H-cadherin in CHO cells regulates contact inhibition of cell growth by inducing p21 expression. Int J Oncol. 24:1573–1579. 2004.PubMed/NCBI

35 

Mukoyama Y, Zhou S, Miyachi Y and Matsuyoshi N: T-cadherin negatively regulates the proliferation of cutaneous squamous carcinoma cells. J Invest Dermatol. 124:833–838. 2005. View Article : Google Scholar : PubMed/NCBI

36 

Huang ZY, Wu Y, Hedrick N and Gutmann DH: T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression. Mol Cell Biol. 23:566–578. 2003. View Article : Google Scholar : PubMed/NCBI

37 

Hermiston ML and Gordon JI: Inflammatory bowel disease and adenomas in mice expressing a dominant negative N-cadherin. Science. 270:1203–1207. 1995. View Article : Google Scholar : PubMed/NCBI

38 

Behrens J: The role of cell adhesion molecules in cancer invasion and metastasis. Breast Cancer Res Treat. 24:175–184. 1993. View Article : Google Scholar : PubMed/NCBI

39 

Pecina-Slaus N: Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 3:172003. View Article : Google Scholar : PubMed/NCBI

40 

Venza M, Visalli M, Catalano T, Biondo C, Beninati C, Teti D and Venza I: DNA methylation-induced E-cadherin silencing is correlated with the clinicopathological features of melanoma. Oncol Rep. 35:2451–2460. 2016. View Article : Google Scholar : PubMed/NCBI

41 

Tamura G, Yin J, Wang S, Fleisher AS, Zou T, Abraham JM, Kong D, Smolinski KN, Wilson KT, James SP, et al: E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 92:569–573. 2000. View Article : Google Scholar : PubMed/NCBI

42 

Hibi K, Kodera Y, Ito K, Akiyama S and Nakao A: Methylation pattern of CDH13 gene in digestive tract cancers. Br J Cancer. 91:1139–1142. 2004.PubMed/NCBI

43 

Schoumacher M, Goldman RD, Louvard D and Vignjevic DM: Actin, microtubules and vimentin intermediate filaments cooperate for elongation of invadopodia. J Cell Biol. 189:541–556. 2010. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Lin J, Chen Z, Huang Z, Chen F, Ye Z, Lin S and Wang W: Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro. Exp Ther Med 14: 4194-4200, 2017.
APA
Lin, J., Chen, Z., Huang, Z., Chen, F., Ye, Z., Lin, S., & Wang, W. (2017). Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro. Experimental and Therapeutic Medicine, 14, 4194-4200. https://doi.org/10.3892/etm.2017.5090
MLA
Lin, J., Chen, Z., Huang, Z., Chen, F., Ye, Z., Lin, S., Wang, W."Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro". Experimental and Therapeutic Medicine 14.5 (2017): 4194-4200.
Chicago
Lin, J., Chen, Z., Huang, Z., Chen, F., Ye, Z., Lin, S., Wang, W."Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro". Experimental and Therapeutic Medicine 14, no. 5 (2017): 4194-4200. https://doi.org/10.3892/etm.2017.5090
Copy and paste a formatted citation
x
Spandidos Publications style
Lin J, Chen Z, Huang Z, Chen F, Ye Z, Lin S and Wang W: Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro. Exp Ther Med 14: 4194-4200, 2017.
APA
Lin, J., Chen, Z., Huang, Z., Chen, F., Ye, Z., Lin, S., & Wang, W. (2017). Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro. Experimental and Therapeutic Medicine, 14, 4194-4200. https://doi.org/10.3892/etm.2017.5090
MLA
Lin, J., Chen, Z., Huang, Z., Chen, F., Ye, Z., Lin, S., Wang, W."Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro". Experimental and Therapeutic Medicine 14.5 (2017): 4194-4200.
Chicago
Lin, J., Chen, Z., Huang, Z., Chen, F., Ye, Z., Lin, S., Wang, W."Upregulation of T‑cadherin suppresses cell proliferation, migration and invasion of gastric cancer in vitro". Experimental and Therapeutic Medicine 14, no. 5 (2017): 4194-4200. https://doi.org/10.3892/etm.2017.5090
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team